title: Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men.
abstract: BACKGROUND
  The beneficial effects of testosterone treatment (TT) are debated.
  
  
  METHODS
  Double-blinded, placebo-controlled study of six months TT (gel) in 54 men aged 60-78 with bioavailable testosterone (BioT) <7.3 nmol/L and waist >94 cm randomized to TT (50-100 mg/day, n = 20), placebo (n = 18), or strength training (ST) (n = 16) for 24 weeks. Moreover, the ST group was randomized to TT (n = 7) or placebo (n = 9) after 12 weeks.
  
  
  RESULTS
  Chemokines (MIF, MCP-1, and MIP-1 α ) and lean body mass (LBM), total, central, extremity, visceral, and subcutaneous (SAT) fat mass established by DXA and MRI. Results. From 0 to 24 weeks, MIF and SAT decreased during ST + placebo versus placebo, whereas BioT and LBM were unchanged. TT decreased fat mass (total, central, extremity, and SAT) and increased BioT and LBM versus placebo. MIF levels increased during TT versus ST + placebo. ST + TT decreased fat mass (total, central, and extremity) and increased BioT and LBM versus placebo. From 12 to 24 weeks, MCP-1 levels increased during TT versus placebo and MCP-1 levels decreased during ST + placebo versus placebo.
  
  
  CONCLUSIONS
  ST + placebo was associated with decreased MIF levels suggesting decreased inflammatory activity. TT may be associated with increased inflammatory activity.
authors.affiliation: Department of Endocrinology, Odense University Hospital, 5000 Odense C, Denmark.
authors.forename: D
authors.initials: D
authors.lastname: Glintborg
authors.forename: L L
authors.initials: LL
authors.lastname: Christensen
authors.forename: T
authors.initials: T
authors.lastname: Kvorning
authors.forename: R
authors.initials: R
authors.lastname: Larsen
authors.forename: K
authors.initials: K
authors.lastname: Brixen
authors.forename: D M
authors.initials: DM
authors.lastname: Hougaard
authors.forename: B
authors.initials: B
authors.lastname: Richelsen
authors.forename: J M
authors.initials: JM
authors.lastname: Bruun
authors.forename: M
authors.initials: M
authors.lastname: Andersen
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000375:Aging; D001823:Body Composition; D018932:Chemokine CCL2 / Q000378:metabolism*; D054405:Chemokine CCL3 / Q000378:metabolism*; D018925:Chemokines / Q000378:metabolism; D004311:Double-Blind Method; D005782:Gels; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D019746:Intramolecular Oxidoreductases / Q000378:metabolism*; D008263:Macrophage Migration-Inhibitory Factors / Q000378:metabolism*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D055070:Resistance Training; D013739:Testosterone / Q000378:metabolism / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C111835:CCL2 protein, human; C515429:CCL3 protein, human; D018932:Chemokine CCL2; D054405:Chemokine CCL3; D018925:Chemokines; D005782:Gels; D008263:Macrophage Migration-Inhibitory Factors; D013739:Testosterone; D019746:Intramolecular Oxidoreductases; C515598:MIF protein, human